Insmed (NASDAQ:INSM) CEO William Lewis Sells 2,357 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 2,357 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $175.07, for a total value of $412,639.99. Following the transaction, the chief executive officer directly owned 318,630 shares in the company, valued at approximately $55,782,554.10. This represents a 0.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

William Lewis also recently made the following trade(s):

• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $561,349.91.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total value of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $166.97, for a total value of $1,786,412.03.

Insmed Stock Performance

Shares of NASDAQ:INSM traded down $5.73 during trading on Thursday, reaching $170.27. The stock had a trading volume of 2,588,589 shares, compared to its average volume of 2,142,398. The stock has a fifty day simple moving average of $190.79 and a two-hundred day simple moving average of $151.24. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75. The firm has a market capitalization of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The firm had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The business’s revenue was up 52.4% compared to the same quarter last year. During the same quarter last year, the business earned ($1.27) EPS. As a group, analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on INSM shares. Leerink Partners restated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Rothschild Redb upgraded Insmed to a “strong-buy” rating in a report on Thursday, December 4th. Citigroup reissued an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Wolfe Research set a $167.00 target price on shares of Insmed and gave the stock an “outperform” rating in a research report on Thursday, December 18th. Finally, Evercore ISI reiterated an “outperform” rating and set a $180.00 target price on shares of Insmed in a research note on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $205.64.

Institutional Trading of Insmed

Institutional investors have recently modified their holdings of the company. Darwin Global Management Ltd. raised its stake in shares of Insmed by 5.8% in the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock valued at $2,897,797,000 after purchasing an additional 1,112,824 shares in the last quarter. Vanguard Group Inc. increased its holdings in Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after buying an additional 2,291,328 shares during the period. Capital International Investors increased its holdings in Insmed by 1.0% in the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after buying an additional 74,994 shares during the period. Artisan Partners Limited Partnership raised its stake in shares of Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after buying an additional 1,623,342 shares in the last quarter. Finally, Duquesne Family Office LLC raised its stake in shares of Insmed by 3.0% in the 3rd quarter. Duquesne Family Office LLC now owns 2,423,435 shares of the biopharmaceutical company’s stock valued at $348,999,000 after buying an additional 70,000 shares in the last quarter.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
• Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
• Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
• Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.